Notes
Danish Kroner
Reference
Hesse U, et al. Impact of Delisting ARBs, Apart from Losartan, on ARB Utilisation Patterns in Denmark: Implications for Other Countries. Applied Health Economics and Health Policy : 9 Oct 2013. Available from: URL: http://dx.doi.org/10.1007/s40258-013-0059-4
Rights and permissions
About this article
Cite this article
Reimbursement changes for ARBs brings cost savings in Denmark. PharmacoEcon Outcomes News 690, 10 (2013). https://doi.org/10.1007/s40274-013-0840-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0840-5